Filing Timeline Unclear After Sutent Trial In Rare Pancreatic Cancer Stops Early
Phase III study, halted for efficacy, tested the tyrosine kinase inhibitor in a disease type that strikes about 30 to 50 patients per million of the total afflicted.
Phase III study, halted for efficacy, tested the tyrosine kinase inhibitor in a disease type that strikes about 30 to 50 patients per million of the total afflicted.